HOSTED BY
ELSEVIER

Contents lists available at ScienceDirect

Journal of Acute Disease

journal homepage: www.jadweb.org

Original article http://dx.doi.org/10.1016/j.joad.2016.06.003

Clinical analysis of acute cerebral infarction accompanied with lung cancer

Zheng-Wei Wang*, Pei-Jun Ye

Intensive Care Unit, Affiliated Tumour Hospital of Zhengzhou University, Zhengzhou 450000, China

ARTICLE INFO

Article history:
Received 28 Feb 2016
Received in revised form 1 Apr 2016
Accepted 2 May 2016
Available online 10 Jun 2016

Keywords:
Non-small cell lung cancer
Acute cerebral infarction
Coagulation function
Thrombelastogram

ABSTRACT

Objective: To analyze the characteristic of coagulation function in non-small cell lung cancer patients with acute cerebral infarction as the initial symptom.
Methods: Cases diagnosed as non-small cell lung cancer in our hospital from January 2015 to January 2016 were used for study. Fifteen cases with acute cerebral infarction as the initial symptom were included in experimental group. Thirty-three cases with no initial symptom on acute cerebral infarction were included in control group. Clinical data in patients of two groups were collected, including general information, coagulation function index, thrombelastogram index.
Results: The prothrombin time (PT) [(9.69 ± 1.42) *vs.* (13.04 ± 1.96) s], activated partial thromboplastin time (APTT) [(30.14 ± 5.79) *vs.* (39.34 ± 7.63) s], international normalized ratio (INR) [(0.76 ± 0.10) *vs.* (1.35 ± 0.22)], coagulation reaction time (R) [(4.76 ± 0.79) *vs.* (6.11 ± 0.93) min], and blood clot formation time (K) [(1.73 ± 0.21) *vs.* (6.11 ± 0.93) min] in patients of experimental group were obviously lower than that of in control group. Fibrinogen (FIB) [(5.43 ± 0.89) *vs.* (2.14 ± 0.36) g/L], D-dimer [(0.84 ± 0.17) *vs.* 0.30 ± 0.06) mg/L], the maximum amplitude of thrombus (MA) [(65.62 ± 10.34) *vs.* (48.69 ± 8.61) mm], and α-angle [(68.12 ± 9.51) *vs.* (60.37 ± 10.29) deg] in patients of experimental group were obviously higher than that in control group. PT, APTT, INR, R value, and K value in patients of tumor node metastasis (TNM) Stage III–IV were significantly lower than that in TNM Stage I–II, and FIB, D-dimer, MA, α-angle were all higher than that in patients of TNM Stage I–II. PT, APTT, INR, R value, K value in patients with lymphatic metastasis were significantly lower than that in patients with no lymph node metastasis, and FIB, D-dimer, MA, α-angle were obviously higher than that in patients with no lymph node metastasis.
Conclusions: Patients with non-small cell lung cancer have hypercoagulability and hyperfibrinolysis with acute cerebral infarction as the initial symptom, and coagulation function involved in the development of lung disease.

1. Introduction

Lung cancer is one of the most malignant tumors worldwide. The occurrence rate and case fatality rate of lung cancer in our country are rising in recent year[1,2]. Non-small cell lung cancer is the most common type of lung cancer, which accounts for over 90% of all lung cancers. Patients are lack of clinical symptom in the early stage, and most patients have been developed to advanced stage at the time of diagnosis, and its prognosis conditions is relatively worse. Although the new targeted drug and chemotherapy drug are constantly developing, the survival rate is still very low[3–6]. Some studies have proved that blood in abnormal hypercoagulability state and the abnormal of coagulation function will increase the risk of arterial embolism in the disease progresses of non-small cell lung cancer[7,8]. Acute cerebral infarction is the initial symptom for some patients with lung cancer, and the existence of lung malignancies was found in the process of diagnosis and treatment of cerebral infarction[9,10]. At present, fewer researches have been done on lung cancer patients with acute cerebral infarction as the initial symptom, and also lack of understanding on this kind of clinical features. Correctly understand the changes of coagulation function in the pathogenic process of lung cancer not only help to early predict the occurrence risk of cerebral infarction and prevent the occurrence of cerebral infarction, but

*Corresponding author: Zheng-Wei Wang, Intensive Care Unit, Affiliated Tumour Hospital of Zhengzhou University, Zhengzhou 450000, China.
Tel: +86 13733837685
E-mail: 254146314@qq.com

Peer review under responsibility of Hainan Medical College. The journal implements double-blind peer review practiced by specially invited international editorial board members.

also provide the basis for early diagnosis and screening of lung cancer. In this study, we analyzed the clinical features of acute cerebral infarction accompanied with lung cancer.

2. Materials and methods

2.1. Case data

Cases diagnosed as non-small cell lung cancer in our hospital from January 2015 to January 2016 were selected in this study. Inclusion criteria: age >18 years; patients were diagnosed as non-small cell lung cancer by biopsy pathology; patients were the first time diagnosis and received no anti-cancer treatment before, and have complete clinical data. Exclusion criteria: patients were diagnosed as other types of lung cancer; patients once received the anti-cancer therapies of radiotherapy, chemotherapy, and targeted therapy, *etc.*; patients involved the presence of distant metastases, and had the medical history of ischemic stroke. Patients with acute cerebral infarction as the initial symptom conformed to the diagnostic criteria of acute cerebral infarction in the Fourth National Conference on Cerebrovascular Disease (1995)[11]. New infarction lesions can be explained by using head CT scan to exclude hemorrhage, as well as using skull magnetic resonance imaging scanning and diffusion weighted imaging to confirm the occurrence of long T1, long T2 and high diffusion weighted imaging signals in head.

2.2. Collection methods of clinical information

Case data were conducted with retrospective analysis for patients. General data including gender, age, body mass index (BMI) index, tumor node metastasis (TNM) staging, lymphatic metastasis. Analytical methods of coagulative function index: after taking peripheral blood, coagulation analyzer was used to detect prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), and D-dimer. Thrombelastogram analytical methods: TEG-500 thromboelastography (Haemoscope Company, Hong Kong) was used to detect the maximum amplitude of thrombus (MA), coagulation reaction time (R), blood clot formation time (K), and blood clot formation rate (α-angle).

2.3. Statistical analysis

Data were inputted and analyzed by SPSS version 19.0. Measurement data was expressed by mean ± SD, and *t*-test was used for the analysis between two groups. Enumeration data were expressed by frequency and analyzed by *Chi*-square test. $P < 0.05$ was considered as statistical significance.

3. Results

3.1. General data in patients of two groups

Among the patients with non-small cell lung cancer, 15 cases of acute cerebral infarction as the initial symptom were included in experimental group. Thirty-three cases with no acute cerebral infarction as the initial symptom were included in control group. In experimental group, 10 cases were males and 5 cases were females, with mean age of (58.0 ± 7.0) years, BMI [(22.1 ± 4.5) kg/m^2], 3 cases in TNM Stage I, 5 cases in Stage 2, 5 cases in Stage III, 2 cases in Stage IV, 4 cases in lymphatic metastasis. In control group, 23 cases were males, and 10 cases were females, with mean age of (55.0 ± 8.0) years, BMI [(21.3 ± 4.9) kg/m^2], 6 cases in TNM Stage I, 10 cases in Stage II, 12 cases in Stage III, 5 cases in Stage IV, 9 cases in lymphatic metastasis. According to statistic analysis, gender, age, BMI index, TNM staging, and lymphatic metastasis in patients of experimental group have no difference with patients in control group (Table 1).

Table 1
General data in patients of two groups.

General data	Experimental group (n = 15)	Control group (n = 33)	P
Gender (male/female)	10/5	23/10	> 0.05
Age (year)	58.0 ± 7.0	55.0 ± 8.0	> 0.05
BMI (kg/m^2)	22.1 ± 4.5	21.3 ± 4.9	> 0.05
TNM staging (I/II/III/IV)	3/5/5/2	6/10/12/5	> 0.05
Lymphatic metastasis	4	9	> 0.05

3.2. Coagulation function in patients of two groups

PT, APTT, INR, R, and K in patients of experimental group were obviously lower than that of in control group. FIB, D-dimer, MA, and α-angle in patients of experimental group were significantly higher than that of in control group (Table 2).

Table 2
Coagulation function in patients of two groups.

Parameters	Experimental group (n = 15)	Control group (n = 33)	P
PT (s)	9.69 ± 1.42	13.04 ± 1.96	< 0.05
APTT (s)	30.14 ± 5.79	39.34 ± 7.63	< 0.05
INR	0.76 ± 0.10	1.35 ± 0.22	< 0.05
FIB (g/L)	5.43 ± 0.89	2.14 ± 0.36	< 0.05
D-dimer (mg/L)	0.84 ± 0.17	0.30 ± 0.06	< 0.05
MA (mm)	65.62 ± 10.34	48.69 ± 8.61	< 0.05
R (min)	4.76 ± 0.79	6.11 ± 0.93	< 0.05
K (min)	1.73 ± 0.21	2.48 ± 0.34	< 0.05
α-Angle (deg)	68.12 ± 9.51	60.37 ± 10.29	< 0.05

3.3. Coagulation function in patients of experimental group in different TNM staging

PT, APTT, INR, R, K in patients of TNM Stage III–IV were obviously lower than that of in patients of TNM Stage I–II. FIB, D-dimer, MA, α-angle in patients of experimental group were significantly higher than that of in patients of TNM Stage I–II (Table 3).

Table 3
Coagulation function in patients of experimental group in different TNM staging.

Parameters	TNM stage I–II (n = 8)	TNM stage III–IV (n = 7)	P
PT (s)	12.13 ± 1.98	7.24 ± 1.03	< 0.05
APTT (s)	35.25 ± 6.94	29.14 ± 5.88	< 0.05
INR	0.98 ± 0.13	0.61 ± 0.09	< 0.05
FIB (g/L)	3.98 ± 0.67	6.23 ± 0.72	< 0.05
D-dimer (mg/L)	0.59 ± 0.11	1.09 ± 0.23	< 0.05
MA (mm)	55.34 ± 8.92	71.34 ± 12.35	< 0.05
R (min)	5.23 ± 0.84	3.24 ± 0.56	< 0.05
K (min)	2.04 ± 0.32	1.39 ± 0.18	< 0.05
α-Angle (deg)	63.36 ± 8.22	74.10 ± 11.28	< 0.05